Becton Dickinson and Company
Organization details
- Legal name
- Becton Dickinson and Company
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- New Jersey
- Headquarters city
- Franklin Lakes
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- September
- Ticker symbol
- BDX
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000010795
- EIN
- 22-0760120
- Wikidata ID
- Q813780
Board of directors
-
Bertram L. Scott · DirectorSince 2023
-
Carrie L. Byington · DirectorSince 2023
-
Catherine M. Burzik · DirectorSince 2023
-
Christopher Ian Montague Jones · DirectorSince 2023
-
Claire Fraser · DirectorSince 2023
-
Gregory Hayes · DirectorSince 2025
-
Jacqueline Wright · DirectorSince 2025
-
Jeffrey William Henderson · DirectorSince 2023
-
Joanne Waldstreicher · DirectorSince 2023
-
Marshall O. Larsen · DirectorSince 2023
-
R. Andrew Eckert · DirectorSince 2023
-
Robert Luther Huffines · DirectorSince 2025
-
Thomas E. Polen Jr. · Director · Chairman, CEO and PresidentSince 2026
-
Timothy M. Ring · DirectorSince 2017
-
William M. Brown · DirectorSince 2023
Chief executives
Director election results
Annual meeting of January 27, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.8%
-
95.0%
-
95.1%
-
96.4%
-
96.4%
-
97.7%
-
98.8%
-
99.1%
-
99.2%
-
99.3%
-
99.5%
-
99.5%
Board connections
11 of this board's directors also sit on 20 other boards. 11 are in the same sector.
- via William M. Brown
- via Bertram L. Scott
-
Eikon Therapeutics Inc. Same sectorvia Robert Luther Huffines
- via Bertram L. Scott
-
Exelixis Inc. Same sectorvia Jacqueline Wright
-
Fortrea Holdings Inc. Same sectorvia R. Andrew Eckert
-
Halozyme Therapeutics Inc. Same sectorvia Jeffrey William Henderson
-
Insulet Corporation Same sectorvia Robert Luther Huffines
-
Kyntra Bio Inc. Same sectorvia Jeffrey William Henderson
- via Bertram L. Scott
-
Maravai LifeSciences Holdings Inc. Same sectorvia R. Andrew Eckert
-
Orthofix Medical Inc. Same sectorvia Catherine M. Burzik
- via Gregory Hayes
- via Jeffrey William Henderson
-
Quest Diagnostics Incorporated Same sectorvia Timothy M. Ring
- via Gregory Hayes
-
Seres Therapeutics Inc. Same sectorvia Claire Fraser
-
Structure Therapeutics Inc. Same sectorvia Joanne Waldstreicher
- via Claire Fraser
- via Jacqueline Wright
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $3,375,515
- 22 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Option exercise | +20,239 | $178.94 | $3,621,567 |
| Nov 5, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Sold back to the company | −17,246 | $210.00 | $3,621,660 |
| Nov 5, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Open-market sale | −2,993 | $210.00 | $628,530 |
| Oct 26, 2026 | Feld Michael Officer (EVP, Chief Revenue Officer) | Open-market sale | −76 | $198.13 | $15,058 |
| Sep 28, 2026 | Feld Michael Officer (EVP, Chief Revenue Officer) | Open-market sale | −76 | $183.70 | $13,961 |
| Sep 2, 2026 | Roque Vitor Officer (EVP & Chief Financial Officer) | Shares withheld for tax | −190 | — | — |
| Aug 26, 2026 | Feld Michael Officer (EVP, Chief Revenue Officer) | Open-market sale | −165 | $188.49 | $31,101 |
| Aug 20, 2026 | Feld Michael Officer (EVP, Chief Revenue Officer) | Shares withheld for tax | −1,049 | — | — |
| Aug 13, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Option exercise | +43,278 | $167.25 | $7,238,246 |
| Aug 13, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Sold back to the company | −39,126 | $185.00 | $7,238,310 |
| Aug 13, 2026 | Thomas E. Polen Jr. Director, Officer (Chairman, CEO and President) | Open-market sale | −4,152 | $185.00 | $768,120 |
| Aug 11, 2026 | Goette Roland Officer (EVP and President, EMEA) | Open-market sale | −2,438 | $180.84 | $440,888 |
| Jul 27, 2026 | Feld Michael Officer (EVP, Chief Revenue Officer) | Open-market sale | −75 | $157.13 | $11,785 |
| Jul 2, 2026 | Muhsin Bilal Officer (EVP & President Connected Care) | Shares withheld for tax | −1,935 | — | — |
| Jul 1, 2026 | Muhsin Bilal Officer (EVP & President Connected Care) | Grant or award | +14,342 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Becton Dickinson and Company
Who is the CEO of Becton Dickinson and Company?
Thomas E. Polen Jr. is Becton Dickinson and Company's Chairman, CEO and President.
How many directors are on Becton Dickinson and Company's board?
Becton Dickinson and Company's board has 15 directors: Bertram L. Scott, Carrie L. Byington, Catherine M. Burzik, Christopher Ian Montague Jones, Claire Fraser, Gregory Hayes, Jacqueline Wright, Jeffrey William Henderson, Joanne Waldstreicher, Marshall O. Larsen and 5 others.
Are Becton Dickinson and Company insiders buying or selling shares?
Over the last 12 months, Becton Dickinson and Company insiders made no open-market purchases and sold $3.4 million of shares in 22 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="becton-dickinson-and-company"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.